European Commission Approves Keytruda-Padcev Bladder Cancer Treatment
The European Commission approved Merck’s Keytruda plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
MRK Gets EU Approval
MRK's KEYTRUDA and Padcev approved by European Commission for treatment of muscle-invasive bladder cancer